CVS Health (NYSE: CVS) posted triple-digit earnings growth in the second quarter, yet the stock has continued to slide despite the strong results.
The healthcare giant reported revenue of $106.1 billion for Q2, representing a 7.3% increase year over year, with earnings per share jumping 188% to $2.31.
CVS operates roughly 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care clinics, and serves approximately 87 million pharmacy benefits plan members through its Caremark division.
Its Aetna segment holds the number two position in health insurance market share, according to the most recent National Association of Insurance Commissioners figures.
Following the strong quarter, CVS upgraded its full-year revenue guidance to at least $414 billion, up from an earlier estimate of at least $405 billion, with EPS forecast now ranging from $6.84 to $7.04.
Despite the upgraded guidance, shares have fallen more than 12% over the past month, trimming year-to-date gains down to 17%, as investors focus on potential headwinds ahead.
Analysts remain firmly bullish, with an average price target of $116.08, which sits nearly 25% above the current share price, suggesting the market is underpricing the stock.
Investor concerns center on membership declines expected at Caremark in 2027 and ongoing revenue headwinds tied to the 340B drug pricing program due to manufacturer-imposed restrictions.
The company’s pharmacy benefit manager business also faces regulatory scrutiny, including heightened Federal Trade Commission oversight that led to an antitrust settlement with Caremark in July, along with proposed legislation targeting PBM pricing transparency.
Aetna’s medical benefit ratio improved to 87.4%, but investors remain cautious about whether medical cost trends will stay contained given broader industry inflation in healthcare utilization.
On valuation, CVS trades at less than 12 times forward earnings, compared to rival UnitedHealth Group (NYSE: UNH), which trades at just under 20 times earnings, making CVS look significantly cheaper relative to its closest peer.
CVS has never cut its dividend and has increased it by more than 56% over the past decade, with a current quarterly payout of $2.66 per share, yielding approximately 2.8%.
That yield is more than twice the S&P 500 average, and with a cash payout ratio below 30% of free cash flow, the dividend appears well protected under current operating conditions.
The company’s vertically integrated model, spanning pharmacy retail, pharmacy benefit management, and health insurance, gives it control over nearly every step of the healthcare dollar.
Having operated for 63 years, CVS has demonstrated a consistent ability to adapt to shifting regulatory and market conditions, which underpins confidence in its long-term outlook.
